2,6-xylidine structure
|
Common Name | 2,6-xylidine | ||
---|---|---|---|---|
CAS Number | 87-62-7 | Molecular Weight | 121.180 | |
Density | 1.0±0.1 g/cm3 | Boiling Point | 217.9±0.0 °C at 760 mmHg | |
Molecular Formula | C8H11N | Melting Point | 10-12 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 91.1±0.0 °C | |
Symbol |
GHS07, GHS08, GHS09 |
Signal Word | Warning |
Name | 2,6-dimethylaniline |
---|---|
Synonym | More Synonyms |
Density | 1.0±0.1 g/cm3 |
---|---|
Boiling Point | 217.9±0.0 °C at 760 mmHg |
Melting Point | 10-12 °C(lit.) |
Molecular Formula | C8H11N |
Molecular Weight | 121.180 |
Flash Point | 91.1±0.0 °C |
Exact Mass | 121.089149 |
PSA | 26.02000 |
LogP | 1.86 |
Vapour Pressure | 0.1±0.4 mmHg at 25°C |
Index of Refraction | 1.559 |
Water Solubility | 7.5 g/L (20 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Symbol |
GHS07, GHS08, GHS09 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H312 + H332-H315-H335-H351-H411 |
Precautionary Statements | P261-P273-P280 |
Personal Protective Equipment | Eyeshields;Faceshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter |
Hazard Codes | Xn:Harmful;N:Dangerousfortheenvironment; |
Risk Phrases | R20/21/22;R37/38;R40;R51/53 |
Safety Phrases | S23-S25-S36/37-S61 |
RIDADR | UN 1711 6.1/PG 2 |
WGK Germany | 2 |
RTECS | ZE9275000 |
Packaging Group | II |
Hazard Class | 6.1 |
HS Code | 29214910 |
Precursor 9 | |
---|---|
DownStream 10 | |
HS Code | 2921430090 |
---|---|
Summary | HS:2921430090 toluidines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
Simultaneous Determination of Xylazine and 2,6-Xylidine in Blood and Urine by Auto Solid-Phase Extraction and Ultra High Performance Liquid Chromatography Coupled with Quadrupole-Time of Flight Mass Spectrometry.
J. Anal. Toxicol. 39 , 444-50, (2015) Xylazine as veterinary medicine for sedation, but intoxication cases in humans were identified in the last few years. A highly sensitive method is required for analyzing xylazine and its metabolites i... |
|
A Novel Method for Assessing Drug Degradation Product Safety Using Physiologically-Based Pharmacokinetic Models and Stochastic Risk Assessment.
J. Pharm. Sci. 104 , 3101-19, (2015) Patient safety risk due to toxic degradation products is a potentially critical quality issue for a small group of useful drug substances. Although the pharmacokinetics of toxic drug degradation produ... |
|
Concentrations of dimethylaniline and other metabolites in milk and tissues of dairy cows treated with lidocaine.
Food Addit. Contam. Part A. Chem. Anal. Control. Expo. Risk Assess. 32 , 1256-64, (2015) Lidocaine is a topical anaesthetic drug used in dairy cows for laparotomy (caesarean section, abomasal displacement). Because there are no registered drugs for this indication, it can be applied under... |
o-Xylidine |
2-Amino-1,3-xylene |
2,6-dimethyl-aniline |
Benzene, 2-amino-1,3-dimethyl- |
1-amino-2,6-dimethybenzene |
Benzenamine,2,6-dimethyl |
2,6-xylidine |
2,6-dimethylphenylamine |
2,6-dimethylbenzeneamine |
aniline, 2,6-dimethyl- |
MFCD00007747 |
2-amino-1,3-dimethylbenzene |
Benzenamine, 2,6-dimethyl- |
2,6-Dimethylbenzenamine |
2,6-Dimethylaniline |
2-Amino-m-xylene |
2,5-DIMETHOXYTOLUENE |
1-amino-2,6-dimethylbenzene |
2,6-methylaniline |
EINECS 201-758-7 |
2,6-dimethyl aniline |
Bupivacaine Impurity 8 |